written on 15.04.2014
Tags:
,

Boehringer Ingelheim revenue slide cushioned by Pradaxa sales jump

TAGS: ,

Pradaxa may not be leading the new-age anticoagulant market, but it's certainly leading Boehringer Ingelheim's growth efforts. The blockbuster med made significant gains in 2013 to help offset currency effects and keep operating income up in the face of dwindling sales, the company said Tuesday.

Latest Report